Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVFM NASDAQ:NCNA NASDAQ:NMTR NYSE:OGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVFMEvofem Biosciences$0.01+4.3%$0.01$0.01▼$0.02$1.14M-0.99404,756 shs30,147 shsNCNANuCana$0.03-1.8%$13.55$0.03▼$10.79$200K1.4195.50 million shs167.42 million shsNMTR9 Meters Biopharma$0.00$0.00$0.07▼$6.56$3K1.36315,915 shs9 shsOGENOragenics$1.16-10.8%$2.51$1.03▼$75.60$955K0.65341,558 shs438,043 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVFMEvofem Biosciences-1.08%-1.08%-2.13%+8.24%-7.07%NCNANuCana-18.81%-23.54%-41.01%-21.90%-99.04%NMTR9 Meters Biopharma0.00%-99.72%-99.72%-99.72%-81.82%OGENOragenics-0.76%+3.17%-13.33%-74.30%-95.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVFMEvofem Biosciences0.9014 of 5 stars0.03.00.04.81.40.00.0NCNANuCana2.5789 of 5 stars3.32.00.00.01.72.51.3NMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AOGENOragenics0.135 of 5 stars0.04.00.00.00.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVFMEvofem Biosciences 0.00N/AN/AN/ANCNANuCana 2.50Moderate Buy$5,000.0015,527,850.31% UpsideNMTR9 Meters Biopharma 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVFMEvofem Biosciences$11.39M0.10N/AN/A($2.64) per share0.00NCNANuCanaN/AN/AN/AN/A$1.34 per shareN/ANMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/AOGENOragenicsN/AN/AN/AN/A$0.61 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVFMEvofem Biosciences$52.98M-$0.05N/A∞N/A-46.42%-91.97%-61.93%N/ANCNANuCana-$24.28M-$7.02N/AN/AN/AN/A-319.85%-88.55%8/13/2025 (Estimated)NMTR9 Meters Biopharma-$43.77M-$3.46N/A∞N/AN/A-584.97%-159.45%N/AOGENOragenics-$20.66M-$33.63N/A∞N/AN/A-2,087.95%-486.56%N/ALatest NCNA, EVFM, OGEN, and NMTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2025Q1 2025NCNANuCana-$2.5820-$126.00-$123.4180-$0.63N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVFMEvofem BiosciencesN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVFMEvofem BiosciencesN/A0.110.09NCNANuCanaN/A1.251.25NMTR9 Meters BiopharmaN/A0.590.59OGENOragenicsN/A1.931.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVFMEvofem Biosciences0.22%NCNANuCana44.00%NMTR9 Meters Biopharma22.34%OGENOragenics18.71%Insider OwnershipCompanyInsider OwnershipEVFMEvofem Biosciences0.21%NCNANuCana31.20%NMTR9 Meters Biopharma2.40%OGENOragenics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableNCNANuCana306.08 million4.18 millionNot OptionableNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataOGENOragenics5823,00010.98 millionN/ANCNA, EVFM, OGEN, and NMTR HeadlinesRecent News About These CompaniesOragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa TrialJuly 31, 2025 | finance.yahoo.comOragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical DevelopmentJuly 16, 2025 | globenewswire.comOragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - Seeking AlphaJuly 3, 2025 | seekingalpha.comOragenics stock tumbles after announcing $20 million preferred stock offeringJuly 2, 2025 | investing.comOragenics Completes Approximately $16.5 Million OfferingJuly 2, 2025 | globenewswire.comSarasota biotech company announces $20M public offeringJuly 2, 2025 | businessobserverfl.comBOragenics shares plunge following announcement of $20 million preferred stock saleJuly 1, 2025 | msn.comOragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and WarrantsJuly 1, 2025 | globenewswire.comOragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumJune 11, 2025 | nasdaq.comOragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumJune 10, 2025 | finance.yahoo.comOragenics Inc.June 4, 2025 | wsj.comOragenics, Inc. Announces One-for-Thirty Reverse Stock SplitMay 29, 2025 | finance.yahoo.comOragenics Hosts Neurotrauma Medicine Webinar PresentationMay 20, 2025 | tipranks.comOragenics gains Australia’s nod for concussion therapy trialMay 15, 2025 | uk.investing.comOragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion TreatmentMay 14, 2025 | nasdaq.comOragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in AustraliaMay 13, 2025 | globenewswire.comOragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion ...May 12, 2025 | gurufocus.comOragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic VisionMay 12, 2025 | globenewswire.comOragenics Appoints Janet Huffman as CEO and CFOMay 2, 2025 | tipranks.comOragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury ConferenceApril 23, 2025 | manilatimes.netMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025View Why the American Eagle Stock Rally Isn't Just Speculation Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging By Nathan Reiff | August 4, 2025View Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging 3 Bullish Biotech Stocks With Explosive Growth TrendsBy Chris Markoch | July 21, 2025View 3 Bullish Biotech Stocks With Explosive Growth TrendsNew Catalyst Sends Joby Stock to 52-Week HighsBy Jeffrey Neal Johnson | July 15, 2025View New Catalyst Sends Joby Stock to 52-Week HighsNCNA, EVFM, OGEN, and NMTR Company DescriptionsEvofem Biosciences NASDAQ:EVFM$0.0096 +0.00 (+4.35%) As of 12:12 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.NuCana NASDAQ:NCNA$0.03 0.00 (-1.83%) Closing price 04:00 PM EasternExtended Trading$0.03 0.00 (-5.59%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.9 Meters Biopharma NASDAQ:NMTR$0.0002 0.00 (0.00%) As of 08/6/20259 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.Oragenics NYSE:OGEN$1.16 -0.14 (-10.77%) Closing price 04:00 PM EasternExtended Trading$1.15 -0.01 (-0.86%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
